TABLE 1.

Effects of XNT on the cardiac activity and expression of ACE2 and ACE.

	Activity (ΔRFU/min/μg)			mRNA (a.u.)			Protein (a.u.)
	CTL	STZ	STZ+XNT	CTL	STZ	STZ+XNT	CTL	STZ	STZ+XNT
ACE2	0.49±0.07	0.54±0.06	0.76±0.06*†	1.00±0.06	1.42±0.18	2.34±0.41*	0.34±0.05	0.24±0.03	0.41±0.11
ACE	1.11±0.18	1.42±0.26	1.58±0.21	1.00±0.05	1.05±0.03	0.82±0.04*†	0.087±0.002	0.26±0.03*	0.150±0.003†
ACE2/ACE	0.44±0.10	0.38±0.08	0.48±0.07	1.00±0.07	1.34±0.18	2.85±0.52*†	3.93±0.55	0.95±0.17*	2.73±0.71

The data are shown as mean ± S.E.M. Activity: ACE2 (n=4, 60μg), ACE (n=4, 30μg). mRNA: ACE2 and ACE (n=4). Protein: ACE2 and ACE (n=3, 1:1000), GAPDH (1:30000). Please see the representative blots in the Supplementary data.

^*P<0.05 vs. Control (CTL) group and

^†P<0.05 vs. Diabetes (STZ) group. Kruskal-Wallis analysis followed by the Dunn’s post test or One-way ANOVA followed by the Newman-Keuls post test (activity).